Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

The American heart journal, 2014-11, Vol.168 (5), p.682-689.e1 [Peer Reviewed Journal]

The Authors ;2014 The Authors ;Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Nov 2014 ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2014.07.028 ;PMID: 25440796 ;CODEN: AHJOA2

Full text available